Deliver Your News to the World

Pharmexa receives US patent on the GV1001 vaccine


Hørsholm, April 24, 2006, The US patent authorities have now issued a patent to Pharmexa on the GV1001 vaccine. GV1001 is Pharmexa’s peptide vaccine targeting telomerase, which is currently under preparation for Phase III trials in pancreatic cancer. Pharmexa already has issued and validated patents for the GV1001 vaccine in Europe and Australia.

Pharmexa’s issued patent claims cover specific peptides, including the GV1001 vaccine, and their use in cancer immunotherapy. In addition, divisional patent applications have been filed in both Europe and the USA.

Jakob Schmidt
Chief Executive Officer

Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa’s proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, rheumatoid arthritis, bone degeneration and Alzheimer’s disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine about to enter phase III trials in pancreatic cancer, HER-2 AutoVac Protein, a recombinant protein vaccine in phase II against breast cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include Schering-Plough, H. Lundbeck, Innogenetics and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 100 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.